Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals
Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals
Status: Archived
Johns Hopkins University
2326
mi
from 98109
Baltimore, MD
Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals
Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals
Status: Archived
Updated: 1/1/1970
Johns Hopkins University
2326
mi
from 98109
Baltimore, MD
Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers
Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate In Healthy Volunteers
Status: Archived
Johns Hopkins University
2326
mi
from 98109
Baltimore, MD
Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers
Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate In Healthy Volunteers
Status: Archived
Updated: 1/1/1970
Johns Hopkins University
2326
mi
from 98109
Baltimore, MD
Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers
Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate In Healthy Volunteers
Status: Archived
University of North Carolina Hospital at Chapel Hill
2329
mi
from 98109
Chapel Hill, NC
Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers
Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate In Healthy Volunteers
Status: Archived
Updated: 1/1/1970
University of North Carolina Hospital at Chapel Hill
2329
mi
from 98109
Chapel Hill, NC
Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients
A Randomized Controlled Pilot Trial Comparing Continued Antiretroviral Therapy With Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) With Switch to Tenofovir/Emtricitabine/Raltegravir (TDF/FTC/RAL) on Changes in Endothelial Function and Markers of Bone Metabolism
Status: Archived
Indiana Univeristy School of Medicine
1867
mi
from 98109
Indianapolis, IN
Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients
A Randomized Controlled Pilot Trial Comparing Continued Antiretroviral Therapy With Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) With Switch to Tenofovir/Emtricitabine/Raltegravir (TDF/FTC/RAL) on Changes in Endothelial Function and Markers of Bone Metabolism
Status: Archived
Updated: 1/1/1970
Indiana Univeristy School of Medicine
1867
mi
from 98109
Indianapolis, IN
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Status: Archived
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Status: Archived
Fenway Community Health Center
2485
mi
from 98109
Boston, MA
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Addressing Psychosocial Needs and HIV Risk in Indian MSM
Status: Archived
Updated: 1/1/1970
Fenway Community Health Center
2485
mi
from 98109
Boston, MA
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Clinical Trial Facility
1782
mi
from 98109
Little Rock, AR
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1782
mi
from 98109
Little Rock, AR
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Clinical Trial Facility
711
mi
from 98109
Santa Clara, CA
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
711
mi
from 98109
Santa Clara, CA
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Clinical Trial Facility
2550
mi
from 98109
Celebration, FL
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2550
mi
from 98109
Celebration, FL
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Clinical Trial Facility
2178
mi
from 98109
Atlanta, GA
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2178
mi
from 98109
Atlanta, GA
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Clinical Trial Facility
1770
mi
from 98109
Austin, TX
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1770
mi
from 98109
Austin, TX
Early Immune Responses to Vaccination - A Substudy to HVTN 205
Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205
Status: Archived
Alabama Vaccine Research Center
2072
mi
from 98109
Birmingham, AL
Early Immune Responses to Vaccination - A Substudy to HVTN 205
Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205
Status: Archived
Updated: 1/1/1970
Alabama Vaccine Research Center
2072
mi
from 98109
Birmingham, AL
Early Immune Responses to Vaccination - A Substudy to HVTN 205
Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205
Status: Archived
San Francisco Vaccine and Prevention CRS
680
mi
from 98109
San Francisco, CA
Early Immune Responses to Vaccination - A Substudy to HVTN 205
Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205
Status: Archived
Updated: 1/1/1970
San Francisco Vaccine and Prevention CRS
680
mi
from 98109
San Francisco, CA
Early Immune Responses to Vaccination - A Substudy to HVTN 205
Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205
Status: Archived
Fred Hutchison Center for Cancer Research
2
mi
from 98109
Seattle, WA
Early Immune Responses to Vaccination - A Substudy to HVTN 205
Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205
Status: Archived
Updated: 1/1/1970
Fred Hutchison Center for Cancer Research
2
mi
from 98109
Seattle, WA
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Pacific Oaks Medical Group
959
mi
from 98109
Beverly Hills, CA
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Pacific Oaks Medical Group
959
mi
from 98109
Beverly Hills, CA
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Providence Clinical Research
954
mi
from 98109
San Fernando Valley, CA
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Providence Clinical Research
954
mi
from 98109
San Fernando Valley, CA
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Peter J. Ruane, MD, Inc.
959
mi
from 98109
Los Angeles, CA
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Peter J. Ruane, MD, Inc.
959
mi
from 98109
Los Angeles, CA
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Washington Hospital Center
2322
mi
from 98109
Washington,
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Washington Hospital Center
2322
mi
from 98109
Washington,
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Gary Richmond, MD, PA
2718
mi
from 98109
Fort Lauderdale, FL
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Gary Richmond, MD, PA
2718
mi
from 98109
Fort Lauderdale, FL
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Orlando Immunology Center
2547
mi
from 98109
Orlando, FL
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Orlando Immunology Center
2547
mi
from 98109
Orlando, FL
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Vita Research Solutions, Inc.
2710
mi
from 98109
Tamarac, FL
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Vita Research Solutions, Inc.
2710
mi
from 98109
Tamarac, FL
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
AIDS Research Consortium of Atlanta
2178
mi
from 98109
Atlanta, GA
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
AIDS Research Consortium of Atlanta
2178
mi
from 98109
Atlanta, GA
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Northstar Medical Center
1730
mi
from 98109
Chicago, IL
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Northstar Medical Center
1730
mi
from 98109
Chicago, IL
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Albany Medical Center Hospital
2352
mi
from 98109
Albany, NY
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Albany Medical Center Hospital
2352
mi
from 98109
Albany, NY
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Aaron Diamond AIDS Research Center (ADARC)
2402
mi
from 98109
New York, NY
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Aaron Diamond AIDS Research Center (ADARC)
2402
mi
from 98109
New York, NY
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Central Texas Clinical Research
1770
mi
from 98109
Austin, TX
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Central Texas Clinical Research
1770
mi
from 98109
Austin, TX
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Therapeutic Concepts, P.A.
1892
mi
from 98109
Houston, TX
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
Therapeutic Concepts, P.A.
1892
mi
from 98109
Houston, TX
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
DCH Cancer Treatment Center
2058
mi
from 98109
Tuscaloosa, AL
A Study of Anti-HIV Monoclonal Antibody KD-247
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Status: Archived
Updated: 1/1/1970
DCH Cancer Treatment Center
2058
mi
from 98109
Tuscaloosa, AL
CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression
Status: Archived
Los Angeles County-USC Medical Center
962
mi
from 98109
Los Angeles, CA
CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression
Status: Archived
Updated: 1/1/1970
Los Angeles County-USC Medical Center
962
mi
from 98109
Los Angeles, CA
CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression
Status: Archived
UC San Diego Medical Center
1063
mi
from 98109
San Diego, CA
CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression
Status: Archived
Updated: 1/1/1970
UC San Diego Medical Center
1063
mi
from 98109
San Diego, CA
CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression
Status: Archived
Harbor UCLA Medical Center
976
mi
from 98109
Torrance, CA
CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression
Status: Archived
Updated: 1/1/1970
Harbor UCLA Medical Center
976
mi
from 98109
Torrance, CA
Epigenetic Markers of B-Cell Function in Low Birth Weight Infants
Epigenetic Markers of B-Cell Function in Low Birth Weight Infants
Status: Archived
University of Utah
703
mi
from 98109
Salt Lake City, UT
Epigenetic Markers of B-Cell Function in Low Birth Weight Infants
Epigenetic Markers of B-Cell Function in Low Birth Weight Infants
Status: Archived
Updated: 1/1/1970
University of Utah
703
mi
from 98109
Salt Lake City, UT
Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers
Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers
Status: Archived
National Institutes of Health Clinical Center
2315
mi
from 98109
Bethesda, MD
Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers
Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers
Status: Archived
Updated: 1/1/1970
National Institutes of Health Clinical Center
2315
mi
from 98109
Bethesda, MD
Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)
Efficacy of CBT for Adherence and Depression in HIV Care Settings
Status: Archived
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)
Efficacy of CBT for Adherence and Depression in HIV Care Settings
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)
Efficacy of CBT for Adherence and Depression in HIV Care Settings
Status: Archived
Fenway Community Health Center
2485
mi
from 98109
Boston, MA
Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)
Efficacy of CBT for Adherence and Depression in HIV Care Settings
Status: Archived
Updated: 1/1/1970
Fenway Community Health Center
2485
mi
from 98109
Boston, MA
Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)
Efficacy of CBT for Adherence and Depression in HIV Care Settings
Status: Archived
The Miriam Hospital Weight Control and Diabetes Research Center
2486
mi
from 98109
Providence, RI
Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)
Efficacy of CBT for Adherence and Depression in HIV Care Settings
Status: Archived
Updated: 1/1/1970
The Miriam Hospital Weight Control and Diabetes Research Center
2486
mi
from 98109
Providence, RI
Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)
Efficacy of CBT for Adherence and Depression in HIV Care Settings
Status: Archived
Butler Hospital Memory & Aging Program
2486
mi
from 98109
Providence, RI
Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)
Efficacy of CBT for Adherence and Depression in HIV Care Settings
Status: Archived
Updated: 1/1/1970
Butler Hospital Memory & Aging Program
2486
mi
from 98109
Providence, RI
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Pfizer Investigational Site
979
mi
from 98109
Los Angeles, CA
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
979
mi
from 98109
Los Angeles, CA
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Pfizer Investigational Site
1010
mi
from 98109
Arvada, CO
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
1010
mi
from 98109
Arvada, CO
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
PI-Coor Clinical Research, LLC
2314
mi
from 98109
Burke, VA
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Updated: 1/1/1970
PI-Coor Clinical Research, LLC
2314
mi
from 98109
Burke, VA
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Pfizer Investigational Site
2075
mi
from 98109
Ashland, KY
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
2075
mi
from 98109
Ashland, KY
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Darien Pediatric Associates
2414
mi
from 98109
Darien, CT
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Updated: 1/1/1970
Darien Pediatric Associates
2414
mi
from 98109
Darien, CT
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Pfizer Investigational Site
1801
mi
from 98109
Cape Girardeau, MO
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
1801
mi
from 98109
Cape Girardeau, MO
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Pfizer Investigational Site
2168
mi
from 98109
Bristol, TN
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
2168
mi
from 98109
Bristol, TN
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Pfizer Investigational Site
1892
mi
from 98109
Houston, TX
Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
1892
mi
from 98109
Houston, TX
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression
Status: Archived
Moores Cancer Center
1049
mi
from 98109
La Jolla, CA
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression
Status: Archived
Updated: 1/1/1970
Moores Cancer Center
1049
mi
from 98109
La Jolla, CA
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression
Status: Archived
Northwestern University
1733
mi
from 98109
Chicago, IL
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression
Status: Archived
Updated: 1/1/1970
Northwestern University
1733
mi
from 98109
Chicago, IL
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression
Status: Archived
Cornell Medical Center
2402
mi
from 98109
New York, NY
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression
Status: Archived
Updated: 1/1/1970
Cornell Medical Center
2402
mi
from 98109
New York, NY
Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
Open Label, Randomized Trial of TDF/FTC+Raltegravir Vs. TDF/FTC+Efavirenz in HIV-1-Infected Women: Differential Effects on Viral Suppression/Reservoir, & Immune Parameters in Different Compartments, Including Gut & Genital Tract
Status: Archived
Mount Sinai Hospital
2401
mi
from 98109
New York, NY
Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
Open Label, Randomized Trial of TDF/FTC+Raltegravir Vs. TDF/FTC+Efavirenz in HIV-1-Infected Women: Differential Effects on Viral Suppression/Reservoir, & Immune Parameters in Different Compartments, Including Gut & Genital Tract
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
2401
mi
from 98109
New York, NY